Search | VHL Regional Portal

Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

Jindani, Amina; Atwine, Daniel; Grint, Daniel; Bah, Boubacar; Adams, Jack; Ticona, Eduardo Rómulo; Shrestha, Bhabana; Agizew, Tefera; Hamid, Saeed; Jamil, Bushra; Byamukama, Adolf; Kananura, Keneth; Mugisha Taremwa, Ivan; Bonnet, Maryline; Camara, Lansana Mady; Bah-Sow, Oumou Younoussa; Bah, Kindy Sadio; Bah, Nene Mamata; Sow, Maimouna; Ticona Huaroto, César Eduardo; Mugruza Pineda, Raquel; Tandukar, Bijesh; Raya, Bijendra Bhakta; Shrestha, Neko; Mathoma, Anikie; Mathebula-Modongo, Unami P; Basotli, Joyce; Irfan, Muhammad; Begum, Dilshad; Muzammil, Ammara; Ahmed, Imran; Hasan, Rumina; Burgos, Marcos V; Sultan, Faisal; Hassan, Mariam; Masood, Iqra; Robb, Claire; Decker, Jonathan; Grubnic, Sisa; Butcher, Philip D; Witney, Adam; Dhillon, Jasvir; Munshi, Tulika; Fielding, Katherine; Harrison, Thomas S.

NEJM Evid ; 2(9): EVIDoa2300054, 2023 Sep.

Article in English | MEDLINE | ID: mdl-38320155

ABSTRACT

High-Dose Rifampicin Regimen for Pulmonary TuberculosisThis randomized, controlled trial tested the efficacy and safety of high-dose rifampicin (1200 or 1800 mg/d) as part of the treatment regimen for pulmonary tuberculosis. Four-month high-dose rifampicin regimens had no dose-limiting side effects but failed to meet noninferiority criteria compared with the standard 6-month control regimen.

Subject(s)

Rifampin , Tuberculosis, Pulmonary , Humans , Rifampin/adverse effects , Antitubercular Agents/adverse effects , Isoniazid/therapeutic use , Drug Therapy, Combination , Tuberculosis, Pulmonary/chemically induced

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL